Glucagon-like peptide-2 (GLP-2) has recently been identified as a stimulator of intestinal epithelial growth, prompting the development of RIA and HPLC methodologies to study this peptide in more detail. A GLP-2-specific antiserum (UTTH-7) was developed that recognizes amino acids 25-30 of human and rat GLP-2-(1-33). UTTH-7 crossreacts with N-and C-terminally modified forms of GLP-2, proglucagon, and the major proglucagon fragment. Analysis of rat ileal extracts demonstrated the presence of GLP-2-(1-33) as well as significant amounts of GLP-2-(3-33) (16 Ϯ 7% of total GLP-2). The level of total immunoreactive GLP-2 in plasma from fasted rats was 700 Ϯ 71 pg/ml, and this increased 3.6-fold (P Ͻ 0.001) in 24-h fed rats. HPLC analysis demonstrated the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fasted rats, with increments in both peptides in plasma from fed rats. Immunoreactive GLP-2 increased in plasma from human subjects 2 h after a meal, rising from 851 Ϯ 230 to 1106 Ϯ 211 pg/ml (P Ͻ 0.05); 15 Ϯ 4% of this immunoreactivity was accounted for by the presence of intact GLP-2. HPLC showed the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fed humans. Incubation of human GLP-2-(1-33) with the enzyme dipeptidylpeptidase IV resulted in liberation of GLP-2-(3-33), whereas replacement of Ala 2 with Gly 2 prevented this cleavage. Thus, while GLP-2-(1-33) is a major circulating and tissue form of GLP-2, GLP-2-(3-33) is a significant component of immunoreactive GLP-2 in both intestine and plasma. (Endocrinology 138: [4837][4838][4839][4840][4841][4842][4843] 1997) 
T ISSUE-SPECIFIC cleavage of proglucagon in the pancreatic A and intestinal L cell gives rise to a distinct profile of proglucagon-derived peptides (PGDPs) in each tissue. Glucagon and the major proglucagon fragment [MPGF; contains glucagon-like peptide-1 (GLP-1) and GLP-2] predominate in the A cell, whereas glicentin, oxyntomodulin, GLP-1, and GLP-2 constitute the intestinal proglucagon-derived peptides (1) (2) (3) (4) (5) (6) . Identification of GLP-1 as a potent regulator of glucose-dependent insulin secretion stimulated the development of RIAs that have now been used in many studies to describe the control of GLP-1 synthesis, secretion, and metabolism (1) (2) (3) (5) (6) (7) (8) (9) (10) (11) (12) . In contrast, lack of a known biological function for GLP-2 has resulted in a comparative paucity of studies on this intestinal PGDP. To date, only three GLP-2 RIAs have been developed, and only limited information is available on the molecular forms of this peptide in pancreas and intestine of the rat, pig, and human (1, 2, 10 -14) . Most of these studies, including those on rat tissues, used molecular sieving approaches for the separation of GLP-2 and related peptides, thereby precluding the detection of any closely related peptides of similar mol wt. Furthermore, the circulating forms of GLP-2 have not been extensively studied, with only a single report describing the release of immunoreactive human (h) GLP-2 into the circulation after a meal (12) .
We have recently identified GLP-2 as a stimulator of intestinal epithelial proliferation (15) (16) (17) . Subcutaneous administration of GLP-2 to mice twice daily for 10 days induces a 1.5-to 2-fold increment in small intestine weight. These changes occur consequent to stimulation of crypt cell proliferation and result in increased villous height (15) (16) (17) . The establishment of a biological activity for GLP-2 has therefore necessitated the development of specific RIA and HPLC methods to analyze the synthesis, secretion, and molecular forms of this peptide so that its regulation might be studied in detail.
Materials and Methods
Antiserum UTTH-7 was raised against synthetic rat GLP-2-(1-33) by consecutive immunization of a New Zealand White rabbit (Cocalico Biologicals, Reamstown, PA). The final antiserum dilution used was 1:25,000, which gives approximately 35% binding of the tracer. As neither rat nor human GLP-2-(1-33) contains a Tyr residue for iodination, tracer was initially prepared by iodination of His 1 using the chloramine-T method, as described for His iodination of secretin (18 Tracer was purified to a specific activity of 600 Ci/mmol by reverse phase adsorption to a cartridge of C 18 silica (Waters Associates, Milford, MA) and elution with 80% (vol/vol) isopropanol containing 0.1% (vol/vol) trifluoroacetic acid (TFA), as described previously (4 -6, 19) . The standard used was human GLP-2-(1-34) (Peninsula Laboratories, Belmont, CA), although antiserum UTTH-7 bound rat GLP-2-(1-33) equally (data not shown). RIA was carried out according to the protocol described by Orskov and Holst (12), with a 6-day incubation of stan-dards/samples (in 0.2 ml), tracer (5000 cpm in 0.1 ml), and antiserum (in 0.1 ml) in Tris buffer (0.1 m Tris, 0.05 m NaCl, 20 mm EDTA, 0.6 mm thimerosol, 400,000 kallikrein inhibitory units/liter Trasylol, and 2 g/ liter human serum albumin), followed by charcoal separation of bound and free counts (by centrifugation at 1300 ϫ g after a 1-h incubation with 0.023 g Norit A charcoal in 1.5 ml Tris buffer containing 17% normal sheep serum). GLP-2 analogs, glicentin, and intervening peptide-2 for competition curves were synthesized by the American Peptide Co. (Sunnyvale, CA) or California Peptide Research; all other structurally related peptides were obtained from Bachem California (Torrance, CA). The intra-and interassay variations were 3.6% and 8.3%, respectively, and the limits of detection were 10 -2,000 pg/tube. RIA for N-terminal GLP-2 immunoreactivity using antiserum 92160 (a gift from Dr. J. J. Holst, Copenhagen, Denmark) was carried out as described for that using antiserum UTTH-7, with a final antiserum dilution of 1:18,750. RIA for glucagon-containing peptides [glucagon-like immunoreactivity (GLI)] was carried out using antiserum K4023 (Biospecific, Emeryville, CA), which recognizes proglucagon, glicentin, oxyntomodulin, and glucagon, as previously described (4 -6) .
Peptides contained in 5 cm rat ileum or half of a rat pancreas (n ϭ 3) were extracted by homogenization in 1 n HCl containing 5% (vol/vol) formic acid, 1% (vol/vol) TFA, and 1% (wt/vol) NaCl, followed by reverse phase extraction using C 18 silica (4 -6). The tissue protein contents of ileal and pancreatic extracts were 2411 Ϯ 207 and 3027 Ϯ 269 g, respectively, as determined by the Lowry protein assay (20) .
In feeding experiments, rats (n ϭ 4 -5) were fasted for 22-24 h (fasted) or were allowed free access to chow without fasting (fed). Normal human volunteers (males and females, aged 23-32 yr; n ϭ 6) were fasted overnight, and a blood sample was collected before (fasted) and after (fed) a small breakfast, consisting of coffee and a donut (ϳ220 cal). Plasma was also collected from two groups of patients using a protocol approved by the Toronto Hospital ethics committee. In brief, one group of patients (n ϭ 4) was examined before and after abdominal surgery, and a second group of patients with chronic renal failure (n ϭ 6) was studied pre-and postdialysis. All plasma samples were collected into a 10% volume of Trasylol-EDTA-diprotin A [5000 kallikrein inhibitory units/ml (Miles Canada, Etobicoke, Canada):1.2 mg/ml:0.1 mm; a dipeptidylpeptidase IV (DP IV; CD26; EC 3.4.14.5) inhibitor (21); Sigma Chemical Co., St. Louis, MO] and were subjected to reverse phase extraction using C 18 silica after addition of 2 vol 1% TFA (pH adjusted to 2.5 with diethylamine) (4).
Proglucagon was obtained by reverse phase extraction of Baby Hamster Kidney (BHK) proglucagon cells, which express the proglucagon gene under the control of a metallothionein promoter, but do not process proglucagon to any of the PGDPs (6, 22) .
HPLC separation of GLP-2-related peptides was carried out using one of three protocols. Separation of proglucagon, glicentin, oxyntomodulin, glucagon, and GLP-2 was accomplished using a C 18 Bondapak column (Waters Associates) with a linear gradient of acetonitrile and TFA [25- 62.5% (vol/vol) B over 45 min, followed by a 10-min purge; A ϭ 1.0% (vol/vol) TFA (pH adjusted to 2.5 with diethylamine); B ϭ 80% (vol/vol) acetonitrile] (4 -6). The flow rate was 1.5 ml/min, and fractions were collected every 18 sec. Trace amounts of [ 125 I]glucagon were added to all samples to serve as an internal control. Mol wt analysis of pancreatic immunoreactive GLP-2 was carried out on two Protein-Pak 125 columns (Waters Associates) in series with isocratic elution using 40% (vol/vol) acetonitrile and 0.1% (vol/vol) TFA. The flow rate was 1 ml/min, and 0.5-min fractions were collected. Cytochrome c (12.5 kDa), Trasylol (6.5 kDa), and [
125 I]glucagon (3.5 kDa) were used as mol wt markers (6). Finally, GLP-2-related peptides in plasma were separated using a gradient of 30 -60% (vol/vol) B over 45 min [A ϭ 0.1% (vol/vol) TFA in water; B ϭ 0.1% (vol/vol) TFA in acetonitrile], followed by a purge. The flow rate was 1.5 ml/min, and 18-sec fractions were collected. Trace amounts of [ 125 I]GLP-2-(1-33)-Tyr 34 were added to all samples as an internal marker.
Incubation of hGLP-2-(1-33) and [Gly 2 ]hGLP-2-(1-33) (from California Peptide Research) was carried out in 40 mm PBS, pH 6.5. Ten micrograms of peptide in 50 l PBS were incubated with 2.5 l (0.125 mU) human DP IV (SA, 5000 mU/mg protein; Calbiochem, San Diego, CA) at 37 C for 24 h. The reaction was quenched by addition of 200 g diprotin A. The samples were then analyzed by HPLC as described above for plasma samples, using a Rainin Dynamax C 18 column (Mandel, Guelph, Ontario, Canada). Elution was monitored by absorption at 214 nm.
Recovery of exogenously added GLP-2 from intestinal, pancreatic, and plasma samples after reverse phase extraction was 84 Ϯ 17%. Statistical analyses were carried out using paired Student's t test or ANOVA with n-1 custom hypotheses tests, as appropriate, using an SAS system for IBM computers (Statistical Analysis Systems, Cary, NC).
Results
The sequences of human and rat GLP-2 are shown in Fig. 1b) . Similarly, binding was not affected by addition of a C-terminal extension to GLP-2 [GLP-2-(1-33)NH 2 ], or removal of the three C-terminal amino acids [GLP-2-(1-30)]. However, antiserum binding of the trace was not displaced by GLP-2-(1-25), which is lacking eight Cterminal amino acids. Thus, the antigenic site recognized by UTTH-7 was localized to amino acids 25 and 30 of GLP-2. UTTH-7 did not bind any other peptides that are structurally related to GLP-2, including other PGDPs (Fig. 1c) .
RIA of rat ileal and pancreatic extracts demonstrated the presence of immunoreactive GLP-2 (189 Ϯ 49 and 100 Ϯ 15 ng, respectively). After separation of the peptides by HPLC, RIA for GLI demonstrated the presence of glicentin and oxyntomodulin, but not of glucagon, in ileal extracts (Fig. 2) . One major peak of immunoreactive GLP-2 was detected that eluted with the same retention time as synthetic rat GLP-2-(1-33). Unexpectedly, variable amounts of a minor peak of GLP-2 were also detected in all samples (16 Ϯ 7% of total GLP-2), which eluted with the same retention time as synthetic rat GLP-2-(3-33). In contrast with the intestinal samples, rat pancreatic extracts contained glucagon, but no other glucagon-containing peptide (e.g. glicentin or oxyntomodulin). No peak of GLP-2 could be detected after HPLC separation of pancreatic peptides despite the detection of immunoreactive peptide in the whole extract before HPLC.
To determine whether the GLP-2 immunoreactivity detected in rat pancreas was due to the presence of large GLP-2-containing peptides such as MPGF, pancreatic samples were subjected to molecular mass analysis. One major peak of immunoreactive GLP-2 was detected, which eluted with a molecular mass consistent with that of MPGF (10 kDa; Fig.  3 ). Antiserum UTTH-7 also cross-reacted with proglucagon, as determined by HPLC and RIA analysis of BHK proglucagon cells (data not shown).
The basal concentration of immunoreactive GLP-2 in plasma from fasted rats was 700 Ϯ 71 pg/ml, and this was increased 3.6-fold (P Ͻ 0.001) in 24-h fed rats (Fig. 4a) . Analysis of the immunoreactive GLP-2 by HPLC demonstrated the existence of three main peaks in plasma from fasted rats, two of which eluted with the same retention time as synthetic GLP-2-(1-33) and GLP-2-(3-33) (Fig. 4b) . The levels of GLP-2-(1-33) and GLP-2-(3-33) were both markedly increased in plasma from fed rats. The minor peak of immunoreactive GLP-2 (fraction 63) has not been identified, but did not change with feeding.
In normal human volunteers, plasma levels of immunoreactive GLP-2 increased from 851 Ϯ 230 to 1106 Ϯ 211 pg/ml 2 h after an approximately 220-cal meal (P Ͻ 0.05; Fig. 5a ). To determine the contribution of intact GLP-2 to these values, a second GLP-2 RIA was established using antiserum 92160, which cross-reacts with the free N-terminal end of rat and human GLP-2, but not with N-terminally truncated forms of GLP-2 (e.g. GLP-2- (3-33) ; Fig. 5a, inset) . Analysis of several of the human plasma samples using antiserum 92160 indicated that GLP-2 levels rose from 116 Ϯ 22 to 197 Ϯ 98 pg/ml 2 h postfeeding. Thus, intact GLP-2 accounts for 15 Ϯ 4% of the total GLP-2 immunoreactivity in human plasma. Total immunoreactive GLP-2 levels were also determined using antiserum UTTH-7 in plasma from patients undergoing ab- dominal surgery as well as dialysis. Pre-and postsurgery concentrations of GLP-2 were not different from those found in normal fasted humans. By contrast, patients with chronic renal failure exhibited markedly increased levels of circulating GLP-2 (4.1-fold vs. normal humans; P Ͻ 0.01), and these levels were not significantly decreased after dialysis. HPLC analysis of plasma from fed humans indicated the presence of two main peaks of GLP-2 that eluted with the same retention times as GLP-2-(1-33) and GLP-2-(3-33) (Fig. 5b) .
We have previously demonstrated that rat GLP-2-(1-33) is cleaved by the enzyme DP IV to liberate GLP-2-(3-33) (23).
To establish whether human GLP-2 is also subject to DP IV-mediated cleavage, hGLP-2-(1-33) was incubated with DP IV, and the products were analyzed by HPLC (Fig. 6a) . Greater than 50% of the hGLP-2-(1-33) was cleaved to GLP-2-(3-33) by DP IV, as confirmed by mass spectrometry and amino acid analysis of the products. To confirm that Ala 2 , a known consensus sequence for DP IV cleavage (24) , is important for the action of DP IV on GLP-2, an analog of GLP-2 was synthesized in which Ala 2 was replaced by Gly 2 ([Gly 2 ]hGLP-2-(1-33)]; this peptide was completely resistant to cleavage by DP IV (Fig. 6b) .
Discussion
The recent demonstration that GLP-2 is a potent stimulator of intestinal epithelial proliferation (15) (16) (17) has stimulated the development of sensitive methods for the detection and characterization of this peptide in tissues and plasma. We report here the characterization of an antiserum that recognizes GLP-2-(25-30) and thus cross-reacts with N-terminally extended and truncated forms of GLP-2 as well as with C-terminally extended GLP-2 and GLP-2 lacking the C-terminal three amino acids. Analysis of BHK proglucagon cells demonstrated that this antiserum also cross-reacts with proglucagon. Thus, antiserum UTTH-7 recognizes many different forms of GLP-2, including potential metabolites as well as precursor proteins.
Consistent with the results of previous studies, the present analyses have demonstrated that GLP-2-(1-33) is liberated from proglucagon in the intestinal L cell, whereas pancreatic GLP-2 is contained within the sequence of MPGF, a large protein that contains the sequences of both GLP-1 and GLP-2 (1, 2, 10, 11) . The results of the present study extend these earlier findings by demonstrating significant amounts of GLP-2-(3-33) in rat ileum. This peptide has not previously been detected by mol wt sieving of rat, pig, or human intestinal tissues (2, 10, 11). However, separation of GLP-2-(1-33) and GLP-2-(3-33) is difficult, requiring reverse phase HPLC with a relatively shallow gradient (ϳ0.67% acetonitrile/min) and a very rapid fraction collection rate (18 sec/fraction).
Immunoreactive GLP-2 levels were elevated 1.5-to 3.6-fold in fed compared with fasted rats and humans, consistent with previous reports of a 50% rise in immunoreactive GLP-2 levels after nutrient ingestion in humans (12) . Similar studies have demonstrated that GLP-1 levels in humans also rise after nutrient ingestion (12, 25) in parallel with the increments in circulating levels of immunoreactive GLP-2 (12) . Such findings are anticipated based upon the known cosynthesis of GLP-1 and GLP-2 from proglucagon within the L cell (1-6). However, the results of the present study further demonstrate that in addition to full-length GLP-2, aminoterminally truncated GLP-2 [e.g. GLP-2-(3-33)] is a major constituent of circulating GLP-2 (50 Ϯ 6% of the total). It must be noted, however, that GLP-2-(1-33) appears to account for only a small percentage of total immunoreactive GLP-2 in the circulation. Thus, the higher levels of total GLP-2 immunoreactivity detected using antiserum UTTH-7 probably reflect contributions from GLP-2-(3-33) as well as pancreatic MPGF.
DP IV-mediated cleavage of rat GLP-2-(1-33) results in the production of GLP-2-(3-33) and appears to be an important determinant of GLP-2 bioactivity (23) . DP IV removes the first two amino acids from proteins containing N-terminal penultimate alanine or proline residues (24) . The results of our experiments establish that human GLP-2 is also subject to DP IV-mediated cleavage. Furthermore, a GLP-2 analog containing glycine at position 2 is resistant to DP IV cleavage, consistent with the importance of Ala 2 for DP IV action. Similar studies on the structurally related hormones GLP-1, glucose-dependent insulinotropic peptide, GH-releasing hormone, and peptide-histidine-methionine, have demonstrated that all of these structurally related peptides that contain alanine at position 2 are also subject to degradation by DP IV (26 -31) . DP IV is distributed in a number of tissues, with the highest levels found in kidney, followed by lung, skin, and intestine (32) . Interestingly, within the small intestine, DP IV concentrations increase in the aboral direction (33) and along the crypt-villous axis (34) . The expression of DP IV within the intestinal epithelium may account for the detection of GLP-2-(3-33) in ileal extracts. However, circulating and/or tissue DP IV may contribute to the presence of larger amounts of GLP-2-(3-33) in plasma. Further studies are clearly required to elucidate the site of degradation of circulating GLP-2. It must be noted, however, that GLP-2-(3-33) was detected in plasma even in the presence of diprotin A, a DP IV-specific inhibitor (21) , thereby suggesting that GLP-2-(3-33) is a normally circulating peptide. These findings emphasize the importance of collection of plasma for GLP-2 analyses in diprotin A to prevent further degradation of the peptide during storage and demonstrate the importance of analytical methods that distinguish between these two forms of the peptide.
Analysis of plasma from a limited number of patients undergoing abdominal surgery did not demonstrate any changes in the circulating levels of GLP-2. It must be noted, however, that this study did not include any patients undergoing resection of the small intestine, which might be expected to alter circulating levels of the intestinal PGDPs, including GLP-2. In contrast, GLP-2 levels were markedly elevated in patients with chronic renal failure, indicating a role for the kidney in the clearance of circulating immunoreactive GLP-2. Renal clearance accounts for removal of a number of the intestinal PGDPs, including glicentin, oxyntomodulin, GLP-1, and GLP-2 (35) (36) (37) . However, most of the circulating immunoreactive GLP-2 in human plasma appears to be consequent to accumulation of immunoreactive peptides other than intact GLP-2, such as truncated GLP-2 and/or MPGF. Thus, the results of these studies clearly demonstrate the need for detailed studies on the clearance of GLP-2 and related peptides from the circulation. In summary, the results of the present study demonstrate that GLP-2-(1-33) is a major form of intestinal GLP-2 that is released into the circulation in both rats and humans. However, GLP-2-(3-33), a degradation product produced by the actions of DP IV, is present in both the intestine and circulation, implicating this enzyme as a regulator of the molecular forms of GLP-2 in vivo.
